POWDER FOR ORAL SUSPENSION

CEFPROZIL 

PHARMACOTHERAPEUTIC GROUP

Antibacterial agent for systemic use belonging to the cephalosporin class.

Ø  1.THERAPEUTIC INDICATIONS

PROLIZIP is indicated for the treatment of the following infections supported by sensitive bacteria:

-upper airway infections including pharyngitis, tonsillitis, sinusitis and otitis media;

-lower airway infections including bronchitis and pneumonia ;

-skin infections ;

-uncomplicated urinary tract infections, including acute cystitis.

Ø  2.DOSAGE AND METHOD OF ADMINISTRATION

PROLIZIP can be administered independently of food intake, ëhich does not affect the absorption.

Adults and children over 12 years
PROLIZIP is given orally in the treatment of infections caused by sensitive bacteria, at the following doses:

- Upper airway infections: 500 mg every 24 hours
- Loëer airway infections: 500 mg every 12 hours
- Uncomplicated urinary tract infections: 500 mg every 24 hours
- Skin and related infections:

            mild/moderate: 500 mg every 24 hours in one or two doses

            serious: 500 mg every 12 hours

Children betëeen 6 months and 12 years
Upper respiratory tract infections:
 - Pharyngitis and tonsillitis: 20 mg/kg every 24 hours or 7.5 mg/kg every 12 hours
 - Otitis media: 15 mg/kg every 12 hours